Payment overview · 2025
General Payments
$45.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Greg A Wise, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GROVEPORT, OH · NPI 1366413940
Verified facts
What the public records show
CMS Open Payments records show Greg A Wise, M.D. received $45.00 in general payments during 2025 across 1 reported records.
Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 135 |
| Losartan Potassium | Losartan Potassium | 465 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 447 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 93 |
| Potassium Chloride | Potassium Chloride | 318 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 59 |
| Furosemide | Furosemide | 171 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 45 |
| Gabapentin | Gabapentin | 157 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 43 |
| Glimepiride | Glimepiride | 140 | 32 |
| Sertraline Hcl | Sertraline Hcl | 140 | 36 |
| Carvedilol | Carvedilol | 139 | 38 |
| Buspirone Hcl | Buspirone Hcl | 116 | 18 |
| Omeprazole | Omeprazole | 114 | 31 |
| Eliquis | Apixaban | 106 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 25 |
| Prednisone | Prednisone | 94 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 24 |
| Famotidine | Famotidine | 77 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 24 |
| Simvastatin | Simvastatin | 72 | 18 |
| Warfarin Sodium | Warfarin Sodium | 72 | 16 |
| Finasteride | Finasteride | 65 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Trazodone Hcl | Trazodone Hcl | 60 | 19 |
| Telmisartan | Telmisartan | 57 | 16 |
| Meloxicam | Meloxicam | 55 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Metformin Hcl | Metformin Hcl | 54 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 14 |
| Lisinopril | Lisinopril | 53 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 37 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 12 |
| Alendronate Sodium | Alendronate Sodium | 43 | 15 |
| Terazosin Hcl | Terazosin Hcl | 42 | 11 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 34 | 19 |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | 11 |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Nabumetone | Nabumetone | 29 | suppressed |
| Jantoven | Warfarin Sodium | 28 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 26 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 14 |
| Topiramate | Topiramate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 17 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.00 · 1 records | Lilly USA, LLC | — | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error